Intra-Cellular Therapies Raises 2023 CAPLYTA Net Product Sales Guidance From $445M-$465M To $460M-$470M
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies has increased its 2023 net product sales guidance for CAPLYTA from $445M-$465M to $460M-$470M.
November 02, 2023 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies' upward revision of its 2023 net product sales guidance for CAPLYTA may positively impact its stock price.
Intra-Cellular Therapies' decision to raise its 2023 net product sales guidance for CAPLYTA indicates a positive outlook for the product's performance. This could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100